For over 10 years we have been committed to developing the latest technology and engineering to help people rethink current physical limitations and achieve the remarkable. Our products unlock human strength, endurance, and mobility potential, with broad applications across medical and industrial markets. In 2016, Ekso Bionics received the first FDA clearance exoskeleton for use with stroke and spinal cord injury levels to C7. We have yet to imagine all human robotics applications and remain committed to forming strategic partnerships for cutting-edge innovation. Ekso Bionics is headquartered in Northern California and listed on the NASDAQ under the symbol EKSO.